<DOC>
	<DOCNO>NCT02212106</DOCNO>
	<brief_summary>This study ass safety bioCSL split virion , inactivated Trivalent Influenza Virus vaccine contain 2014/2015 Northern Hemisphere strain vaccine child age 5 year less 9 year . Comparison make licensed Quadrivalent Influenza Virus vaccine complies FDA recommendation 2014/2015 influenza season US .</brief_summary>
	<brief_title>A Study Evaluate Safety Tolerability Trivalent Influenza Virus Vaccine Children Aged 5 Years &lt; 9 Years</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Males female age 5 less 9 year time first study vaccination . The subject 's parent guardian provide write informed consent willing able adhere protocol requirement . In good health , determine medical history target physical examination ( warrant ) . Known hypersensitivity previous dose Influenza Virus Vaccine allergy egg component study vaccine . Clinical sign significant active infection elevate oral temperature study entry . A clinically significant medical psychiatric condition . A history seizures febrile convulsion GuillainBarr√© syndrome . Vaccination seasonal experimental influenza virus vaccine 6 month precede study entry . Vaccination license vaccine within 14 day precede study entry , plan vaccinate another license vaccine study exit evaluation . Currently receive systemic glucocorticoid therapy ( exclude intraarticular , topical inhale preparation ) receive therapy within 3 month precede study entry . Currently receive immunoglobulin and/or blood product receive treatment within 3 month precede administration study vaccine . Currently receive treatment warfarin anticoagulant .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>8 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>